Does low testosterone have a causative role in promoting worsening cardiovascular health or does it simply mark out a population of less healthy men, or both? The risk of death was greater for men in the lowest baseline quartile of both total and bioavailable testosterone compared with those in the highest quartile. More modern studies have been more consistent in design and definition, especially when the primary hypothesis was related to the question of the link between testosterone blood level and CAD. The metabolic syndrome is a well-recognized risk factor for atherosclerosis and coronary morbidity and mortality. Total testosterone fell at a rate of 0.11 nmol l−1 year−1, but the fall in free testosterone was more impressive and due, at least in part, to the significant rise of sex hormone binding globulin with age. Harman et al.25 investigated the nature and potential aetiological factors involved in the change in sex hormone levels with age in the Baltimore Longitudinal Study of Aging. Testosterone can be described as having anabolic and androgenic (virilising) effects, though these categorical descriptions are somewhat arbitrary, as there is a great deal of mutual overlap between them. In general, androgens such as testosterone promote protein synthesis and thus growth of tissues with androgen receptors. As the metabolism of testosterone in males is more pronounced, the daily production is about 20 times greater in men. Men who watch sexually explicit films also report increased motivation and competitiveness, and decreased exhaustion. Men who watch a sexually explicit movie have an average increase of 35% in testosterone, peaking at 60–90 minutes after the end of the film, but no increase is seen in men who watch sexually neutral films. In non-human primates, it may be that testosterone in puberty stimulates sexual arousal, which allows the primate to increasingly seek out sexual experiences with females and thus creates a sexual preference for females. Sexual arousal and masturbation in women produce small increases in testosterone concentrations. 2020 guidelines from the American College of Physicians support the discussion of testosterone treatment in adult men with age-related low levels of testosterone who have sexual dysfunction. It is unclear if the use of testosterone for low levels due to aging is beneficial or harmful. In 1978, Shahwan et al.74 established that male diabetics have lower levels of endogenous testosterone, compared to nondiabetic men. Proposed mechanisms include hematocrit stimulation–induced platelet aggregation and increased thromboxane A2 receptor density on platelets.72 However, clinical trials have not found corresponding effects on coagulation.73 Further, testosterone has been shown to increase cardiac contractility61 and cardiomyocyte relaxation speed.63 It is not clear whether these vascular effects are dependent on the endothelium and/or AR. It is widely regarded that men display behaviours which are considered, cardiologically, more risky with increased levels of smoking and with diets richer in saturated fats.2 However, multiple logistic regression analysis has shown that differences in behavioural profiles do not account for the excess burden of coronary disease in men.2, 26 The development and progression of coronary atherosclerosis is heavily influenced by the interaction of multiple risk factors. Ties between hypogonadism and cardiovascular disease are suggested by observational data, yet therapy with testosterone replacement has not been shown to mitigate that risk. Clearly, though, it's much more important to see if testosterone therapy can change the risk of actual clinical cardiovascular events. A 2008 study administered an oral testosterone preparation or a placebo to 22 men with coronary artery disease and low testosterone levels. Low testosterone levels have been linked to various cardiac risk factors, but that doesn't prove that low levels actually cause heart disease. A Swedish study of over 3,000 men with an average age of 75 linked low testosterone and high estradiol levels to an increased risk of PAD. T levels were then measured in stored blood samples from initial study visits and analyzed for differences between the two groups. An alternative approach, employed to examine the association between T levels over time and CVD, was a nested case–control study within the Baltimore Longitudinal Study of Aging and the Multiple Risk Factors Intervention Trial . Additional longitudinal studies have similarly found that neither high nor low T levels predict incident myocardial infarction 14–16. In contrast, men in the highest quartile of serum T in the MrOS study had the lowest incidence of CVD events over 5 years of follow-up . These longitudinal analyses, therefore, relate endogenous T levels to the development of disease over time. Certain cytochrome P450 enzymes such as CYP2C9 and CYP2C19 can also oxidize testosterone at the C17 position to form androstenedione. In addition to 6β- and 16β-hydroxytestosterone, 1β-, 2α/β-, 11β-, and 15β-hydroxytestosterone are also formed as minor metabolites. The 6β-hydroxylation of testosterone is catalyzed mainly by CYP3A4 and to a lesser extent CYP3A5 and is responsible for 75 to 80% of cytochrome P450-mediated testosterone metabolism. In addition to conjugation and the 17-ketosteroid pathway, testosterone can also be hydroxylated and oxidized in the liver by cytochrome P450 enzymes, including CYP3A4, CYP3A5, CYP2C9, CYP2C19, and CYP2D6. A small portion of approximately 3% of testosterone is reversibly converted in the liver into androstenedione by 17β-HSD. In the hepatic 17-ketosteroid pathway of testosterone metabolism, testosterone is converted in the liver by 5α-reductase and 5β-reductase into 5α-DHT and the inactive 5β-DHT, respectively. The conjugates of testosterone and its hepatic metabolites are released from the liver into circulation and excreted in the urine and bile. have been undertaken on the relationship between more general aggressive behavior, and feelings, and testosterone. This increases the reproductive fitness of the parents because their offspring are more likely to survive and reproduce.} That's because a report from the Massachusetts Male Aging Study found that over half the men with symptomatic testosterone deficiency improved without any treatment at all. But even if your levels are low, you may benefit from a period of observation and repeat testing before starting treatment. As a rule of thumb, if your total testosterone is above 300 ng/dL, your free testosterone is above 5 ng/dL, or your bioavailable testosterone is above 150 ng/dL, true deficiency is unlikely. But since normal levels vary so widely, how do you know if your results are really low? Experts do not recommend routine testing for testosterone deficiency. According to one survey, only 12% of men with androgen deficiency were receiving treatment. In all, an average, healthy 65-year-old in 2002 had about 15% less testosterone than a similar 65-year-old in 1987. Importantly too, HDL-c concentrations in isolation may not be a reliable marker of CVD risk, since no long-term clinical data have established a link between the lower HDL-c concentrations caused specifically by TRT and increased incidence of CVD. Recently, larger cross-sectional studies have been undertaken to better define the cardiovascular effects of TRT. In fact, a similar study of comparable size and design did not observe such an increase in CVD events among men randomized to the T arm . This randomized controlled trial of elderly, frail men was halted early by the data safety monitoring board due to an excess of cardiovascular events noted among older men randomized to testosterone as compared with placebo.